Celgene Ordered To Turn Over Thalomid Price Data
New Jersey-based drugmaker Celgene Corp. must turn over pricing data on its drug Thalomid to Canadian authorities so they can determine if patients are being gouged, Canada's high court ruled Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article